Skip to main
PGEN
PGEN logo

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen Inc. is poised for potential growth due to the anticipated approval of PRGN-2012, which is expected to establish itself as a leading therapy for recurrent respiratory papillomatosis (RRP), likely increasing awareness and improving diagnostic rates. The strong clinical results, which indicate significant reductions in the need for surgeries among patients, suggest that PRGN-2012 may achieve widespread acceptance among specialists in the field. The company's confidence in obtaining regulatory approval by the August 27, 2025 PDUFA date further underlines its strategic positioning for future commercial success within the biopharmaceutical market.

Bears say

Precigen Inc faces significant challenges in maintaining or growing sales of its existing products due to a competitive market environment and pricing pressures that could jeopardize revenue stability. Furthermore, the company has a history of financial losses and lacks a consistent profitability track record, raising concerns about its long-term financial health. Additionally, the risk associated with its balance sheet underscores potential vulnerabilities that may impact its operations and investment appeal.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.